Kenneth Kirby, the president of TransDermal Delivery Solutions Corp., sees his company?s transdermal drug delivery system as transforming the way we think about medication.
Could transdermal drug delivery really change the way we take our medicine? Kenneth Kirby, President of TransDermal Delivery Solutions Corp. thinks so.
By opting for transdermal delivery over oral delivery, Kirby says the drugs are better able to retain their potency and work factor. A potential downside would be the issue of restrictions on lifestyle activities, since users would be unable to get wet following application for fear of needing to reapply. However, Kirby says the company is working on that issue by adding ethanol to the spray to help it dry faster.
TransDermal Delivery Solutions, and majority-owned subsidiary, Hormone Replacement Technologies, are currently planning for several clinical trials to investigate the delivery mechanism using Testagen TDS, a testosterone treatment. The company's Investigational New Drug application was recently approved by the FDA. The studies will focus on dose range, transference, and comparisons to the gel application.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.